The lawsuits follow an announcement by Novo Nordisk that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers' sales and“deceptive” marketing of the weight ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The breakup comes due to Novo Nordisk’s claims that Hims & Hers has ‘failed to adhere to the law’ by continuing to sell compounded versions of Wegovy. This morning, the Danish pharmaceutical giant ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss drug.

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Hims & Hers Health (NYSE: HIMS) is a telehealth company that offers personalized solutions for its customers. While ...

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...